Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by education grants from: Bristol Myers Squibb, Incyte Corporation, Protagonist Therapeutics, and Sumitomo Dainippon Pharma Oncology.
Advances in MF and PV: Individualizing Care Based on Patient- and Disease-Specific Factors
Release Date: August 31, 2021
Expiration Date: August 31, 2022
This virtual, on-demand webcast is specifically designed to meet the needs of busy clinicians who treat patients who have received a diagnosis of polycythemia vera (PV) or myelofibrosis (MF) by providing an update on optimal risk stratification, treatment selection, and emerging therapeutic options. These didactic presentations are placed into real-world context through discussion of 4 case scenarios spanning the disease continuum for PV and MF. These cases will help place recent findings and treatment recommendations into context for participants.
Acknowledgement of Commercial SupportThis activity is supported by education grants from: Bristol Myers Squibb, Incyte Corporation, Protagonist Therapeutics, and Sumitomo Dainippon Pharma Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients given a diagnosis of a MPN. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MPNs will be invited to participate.
Upon successful completion of this activity, you should be better prepared to:
- Develop an individualized care plan based on genetics, risk stratification, and symptom burden for patients with MF or PV.
- Evaluate safety and efficacy data concerning novel and emerging treatment options for managing MF or PV.
- Outline strategies to identify and manage disease-associated symptoms and treatment-related toxicities in patients given a diagnosis of MF or PV.
- Integrate emerging data into clinical scenarios, with a focus on optimizing care across the MPN disease continuum.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
United Energy Resources, Inc, Professor of Medicine
Director, Hanns A. Pielenz Clinical Research Center
for Myeloproliferative Neoplasms
Chief, Section for Proliferative Neoplasms
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Disclosures: Grant research support: Incyte, Roche, NS Pharma, Celgene, Gilead Sciences, Promedior, CTI BioPharma, AbbVie, Blueprint Medicines, Novartis Pharmaceuticals, Sierra Oncology, PharmaEssentia, Constellation Pharmaceuticals, Italfarmaco SpA, Protagonist Therapeutics, Kartos Therapeutics.
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Disclosures: Grant Research Support: Protagonist Therapeutics, Sierra Oncology, Prelude Therapeutics, Celgene/Bristol Myers Squibb, Incyte; Consultant: Protagonist Therapeutics, AbbVie, Novartis Pharmaceuticals, PharmaEssentia, Incyte; Speaker’s Bureau: Blueprint Medicines, Novartis Pharmaceuticals.
Clinical Director, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant Research Support: Incyte, Stemline Therapeutics, Constellation Pharmaceuticals; Consultant: Incyte, Celgene/Bristol Myers Squibb, Disc Medicine, Sierra Oncology, Novartis Pharmaceuticals, Blueprint Medicines, PharmaEssentia, CTI BioPharma, Stemline Therapeutics, AbbVie, Constellation Pharmaceuticals, Kartos Therapeutics, Jazz Pharmaceuticals.
Associate Professor of Medicine
Clinical Director, Ambulatory Hematology Clinics
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center
University of Kansas Medical Center
Kansas City, KS
Disclosures: Consultant: Novartis Pharmaceuticals, CTI BioPharma, Acceleron Pharma, Agios Pharmaceuticals; Speaker’s Bureau: Incyte, Agios Pharmaceuticals, Novartis Pharmaceuticals.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.